# Comparative Bioavailability of Risperidone

> **NCT03527186** · PHASE1 · COMPLETED · sponsor: **Rovi Pharmaceuticals Laboratories** · enrollment: 81 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone ISM® 100 mg

## Key facts

- **NCT ID:** NCT03527186
- **Lead sponsor:** Rovi Pharmaceuticals Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-09
- **Primary completion:** 2019-03-23
- **Final completion:** 2019-04-06
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2021-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03527186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03527186, "Comparative Bioavailability of Risperidone". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03527186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*